Wilmington Savings Fund Society FSB Sells 2,589 Shares of Boston Scientific Corporation $BSX

Key Points

• Wilmington Savings Fund Society FSB reduced its stake in Boston Scientific Corporation by 12.1%, selling 2,589 shares and maintaining 18,768 shares valued at $2,016,000.
• Company insiders, including EVP Joseph Michael Fitzgerald and EVP Arthur C. Butcher, sold a significant number of shares on August 1, totaling over $7 million in value.
• Boston Scientific’s stock has a market cap of $144.87 billion and recently announced better-than-expected quarterly earnings, reporting a revenue of $5.06 billion and an EPS of $0.75.

Wilmington Savings Fund Society FSB reduced its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 12.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 18,768 shares of the medical equipment provider's stock after selling 2,589 shares during the quarter. Wilmington Savings Fund Society FSB's holdings in Boston Scientific were worth $2,016,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BSX. Brighton Jones LLC boosted its position in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after acquiring an additional 226 shares during the last quarter. GAMMA Investing LLC lifted its position in Boston Scientific by 17.2% in the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider's stock worth $2,578,000 after buying an additional 3,745 shares during the last quarter. Dynamic Advisor Solutions LLC lifted its position in Boston Scientific by 8.1% in the first quarter. Dynamic Advisor Solutions LLC now owns 5,163 shares of the medical equipment provider's stock worth $521,000 after buying an additional 388 shares during the last quarter. Mission Wealth Management LP bought a new stake in Boston Scientific in the first quarter worth $217,000. Finally, Janney Montgomery Scott LLC lifted its position in Boston Scientific by 37.8% in the first quarter. Janney Montgomery Scott LLC now owns 285,463 shares of the medical equipment provider's stock worth $28,798,000 after buying an additional 78,301 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

BSX stock opened at $97.77 on Thursday. The firm has a market cap of $144.87 billion, a price-to-earnings ratio of 58.20, a PEG ratio of 2.32 and a beta of 0.61. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The business's fifty day simple moving average is $101.48 and its two-hundred day simple moving average is $101.77.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of analyst reports. Royal Bank Of Canada restated an "outperform" rating and issued a $125.00 price target on shares of Boston Scientific in a research report on Monday, September 29th. Wells Fargo & Company raised their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Barclays raised their price target on Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a research report on Thursday, October 2nd. Weiss Ratings reiterated a "buy (b-)" rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Finally, Truist Financial increased their target price on Boston Scientific from $125.00 to $129.00 and gave the stock a "buy" rating in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and a consensus target price of $120.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.